| Primary |
| Drug Use For Unknown Indication |
14.7% |
| Sepsis |
12.7% |
| Pneumonia |
9.1% |
| Infection |
8.1% |
| Hypertension |
6.2% |
| Pain |
4.9% |
| Fluid Replacement |
4.6% |
| Neutropenic Sepsis |
4.6% |
| Urinary Tract Infection |
4.6% |
| Prophylaxis |
4.2% |
| Bronchiectasis |
3.6% |
| Cholecystitis |
3.6% |
| Metastatic Gastric Cancer |
2.9% |
| Pyrexia |
2.9% |
| Anti-infective Therapy |
2.3% |
| Epilepsy |
2.3% |
| Lower Respiratory Tract Infection |
2.3% |
| Pneumonia Aspiration |
2.3% |
| Pneumonitis |
2.3% |
| Acute Myeloid Leukaemia |
2.0% |
|
| Rash |
8.6% |
| Interstitial Lung Disease |
6.9% |
| Septic Shock |
6.9% |
| Toxic Skin Eruption |
6.9% |
| White Blood Cell Count Decreased |
6.9% |
| Death |
6.0% |
| Pyrexia |
6.0% |
| Vomiting |
6.0% |
| Dermatitis Exfoliative |
5.2% |
| Thrombocytopenia |
5.2% |
| Megacolon |
4.3% |
| Cardio-respiratory Arrest |
3.4% |
| Jaundice |
3.4% |
| Laryngeal Oedema |
3.4% |
| Liver Disorder |
3.4% |
| Pneumonia Klebsiella |
3.4% |
| Renal Failure Acute |
3.4% |
| Sepsis |
3.4% |
| Shock |
3.4% |
| Skin Haemorrhage |
3.4% |
|
| Secondary |
| Product Used For Unknown Indication |
33.1% |
| Drug Use For Unknown Indication |
16.2% |
| Pneumonia Aspiration |
7.9% |
| Pneumonia |
4.6% |
| Lower Respiratory Tract Infection |
4.1% |
| Pseudomonas Infection |
4.1% |
| Pain |
3.6% |
| Sepsis |
3.3% |
| Cholecystitis |
3.0% |
| Acute Myeloid Leukaemia |
3.0% |
| Respiratory Failure |
2.9% |
| Infection |
2.4% |
| Myelodysplastic Syndrome |
2.1% |
| Pyrexia |
2.1% |
| Staphylococcal Infection |
1.4% |
| Urinary Tract Infection |
1.3% |
| Bacteraemia |
1.2% |
| Epilepsy |
1.2% |
| Peritonitis Bacterial |
1.2% |
| Prophylaxis |
1.2% |
|
| Venoocclusive Liver Disease |
19.8% |
| White Blood Cell Count Increased |
8.8% |
| Toxic Epidermal Necrolysis |
6.0% |
| Intestinal Dilatation |
5.5% |
| Liver Function Test Abnormal |
5.5% |
| Platelet Count Increased |
5.5% |
| Venoocclusive Disease |
5.5% |
| Megacolon |
4.9% |
| Vomiting |
4.4% |
| Dermatitis Exfoliative |
3.3% |
| Interstitial Lung Disease |
3.3% |
| Renal Failure |
3.3% |
| Renal Failure Acute |
3.3% |
| Stevens-johnson Syndrome |
3.3% |
| Toxic Encephalopathy |
3.3% |
| Weight Decreased |
3.3% |
| Clostridium Difficile Infection |
2.7% |
| Nausea |
2.7% |
| Thrombocytopenia |
2.7% |
| Urticaria |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.9% |
| Drug Use For Unknown Indication |
14.4% |
| Prophylaxis |
12.2% |
| Acute Myeloid Leukaemia |
4.9% |
| Hypertension |
4.7% |
| Pneumonia |
4.5% |
| Pain |
3.2% |
| Infection |
2.8% |
| Nausea |
2.8% |
| Antibiotic Therapy |
2.7% |
| Sepsis |
2.3% |
| Diffuse Large B-cell Lymphoma |
2.1% |
| Infection Prophylaxis |
1.8% |
| Pyrexia |
1.8% |
| Ascites |
1.6% |
| Antifungal Prophylaxis |
1.5% |
| Constipation |
1.5% |
| Neoplasm Malignant |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
| Sedation |
1.4% |
|
| Thrombocytopenia |
13.3% |
| Sepsis |
10.3% |
| Pyrexia |
7.0% |
| Septic Shock |
6.6% |
| Renal Failure Acute |
6.3% |
| Pneumonia |
5.0% |
| Tachycardia |
5.0% |
| Toxic Epidermal Necrolysis |
4.7% |
| White Blood Cell Count Decreased |
4.7% |
| White Blood Cell Count Increased |
4.3% |
| Tumour Lysis Syndrome |
4.0% |
| Death |
3.7% |
| Febrile Neutropenia |
3.7% |
| Neutropenia |
3.3% |
| Renal Failure |
3.3% |
| Respiratory Failure |
3.3% |
| Neutropenic Sepsis |
3.0% |
| Urinary Tract Infection |
3.0% |
| Weight Decreased |
3.0% |
| Rash |
2.7% |
|
| Interacting |
| Pleural Effusion |
20.0% |
| Renal Transplant |
20.0% |
| Atrial Fibrillation |
10.0% |
| Deep Vein Thrombosis |
10.0% |
| Interstitial Lung Disease |
10.0% |
| Pneumocystis Jiroveci Pneumonia |
10.0% |
| Pneumonia |
10.0% |
| Urinary Tract Infection Fungal |
10.0% |
|
| Pneumonia |
33.3% |
| Rash |
33.3% |
| Ulcer |
33.3% |
|
